In addition, TMPRSS2:ERG gene fusions secondary to deletions of chromosome 21q22 and increased copy number of the fusion sequences have been associated with improved progression free survival in patients with castrate resistant prostate cancer treated with abiraterone treatment compared to ERG negative or ERG rearranged tumors [48]. This evidence concerns the gene TMPRSS2 and prostate carcinoma.